Link to Full Article LA JOLLA, Calif., December 17, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the treatment of severe acute and chronic inflammatory diseases, today announced that the trial evaluating AuxoraTM in patients with severe COVID-19 pneumonia has received a recommendation to continue, following a […]

Link to Full Article Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline La Jolla, Calif., USA; Szeged and Budapest, Hungary July 15, 2020 – CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels […]

Link to Full Article Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone The percentage of patients requiring invasive mechanical ventilation was 2.8 times lower with Auxora plus standard of care compared to standard of care alone Treating 2.6 […]

Link to Full Article Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone  LA JOLLA, Calif., May 28, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute […]